As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the ...

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of ...

Lunit’s AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche’s navify® Digital Pathology platform to enhance ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

Roche's navify Digital Pathology, an enterprise software application, now features a suite of AI-driven algorithms, including ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

The global cancer biomarkers market size is anticipated to grow from USD 24.08 billion to USD 78.20 billion in 10 years. The market will experience rapid growth due to the rising demand for ...

Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients ...

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual ...

Researchers have identified five independent factors that predict cancer patients' response to checkpoint inhibitors (CPIs). The study validates these factors in more than 1,400 patients and diverse ...